{
  "$schema": "folio-library-entry/v1",
  "id": "10665-231031",
  "blocks": [
    {
      "id": "library/10665-231031/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "Sero-epidemiological data in the age group of children\naged <4 years in 1999 showed a prevalence rate of 0.16%\ncompared to 5.4% in the same age group in 1983, indicating\nthe interruption of vectorial transmission in this country.\n\nTransmission through blood transfusion is under control\ndue to the 100% coverage of compulsory blood screening in\nthe endemic areas.\n\n(Reported by Programa Nacional de Control de la Enferme-\ndad de Chagas, Ministerio de Salud, Santiago, Informe de la\nComisiôn de Certificacién, November 1999.)\n\nEditorial note. These data rank Chile as the second mem-\nber country of th",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A page of the Weekly Epidemiological Record of 14 January 2000, in English and French, reporting that Chile interrupted vector-borne and transfusional transmission of Chagas disease in 1999, the second Southern Cone country after Uruguay to reach these goals. It then sets out WHO's position on thiomersal, a mercury-containing vaccine preservative: WHO supports a July 1999 US statement on phasing it out but stresses that children's vaccines containing it should still be used. Since no tested, safe and effective alternative yet exists, WHO will keep recommending vaccines such as DTP, DT, tetanus toxoid and some hepatitis B and Hib vaccines, an approach endorsed by its Expert Committee on Biological Standardization in November 1999.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-231031/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "supports the continued use of current vaccines that protect\nthe lives of millions of children each year.\n\nThe US report mentioned above made recommendations\nto avoid thiomersal-containing hepatitis B vaccine for\ncertain newborns, including the screening of pregnant\nmothers for the blood marker of the liver infection. WHO\nstresses that this is not an option for developing countries,\nowing to practical constraints and high cost. Instead, the\nOrganization is promoting the development of a single-\ndose, affordable presentation of hepatitis B vaccine that\nwill not require a preservative. This devic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the bilingual Weekly Epidemiological Record note on thiomersal, explaining that screening pregnant women in order to avoid thiomersal-containing hepatitis B vaccine is not workable for developing countries, so WHO is promoting an affordable preservative-free single-dose pouch-and-needle device now in field trials. It summarises what is known about thiomersal toxicity, which is uncertain at low doses and is inferred largely from evidence on methylmercury, and notes that no dose-response curve can be built for vaccine doses. It explains that dietary methylmercury guidelines from WHO and US agencies, ranging from 0.7 to 3.3 µg/kg body weight per week, are therefore used to judge whether vaccine mercury reaches a level of concern, starting from a worst-case low-weight infant.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-231031/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "limits for safe total methylmercury exposure are between\n34 wg (according to EPA standards) and 159 yg (according\nto WHO standards). Table 1 shows the exposure that would\ntake place during a typical national immunization\nschedule. During the first 14 weeks of life, an infant gener-\nally receives 3 doses of DTP vaccine or a total of 75 yg\nof ethylmercury. If hepatitis B vaccine is added to the\nimmunization schedule, the maximum exposure to\nethylmercury during the first 14 weeks of life is 112.5 wg.\nAdding Hib vaccine, the total ethylmercury dose reaches\n187.5 ag. This suggests that some infants",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the bilingual note on thiomersal, calculating that an infant on a typical schedule may receive up to 187.5 µg of ethylmercury from DTP, hepatitis B and Hib vaccines in the first 14 weeks, which may be of concern and exceeds some agencies' cut-off levels. A table sets out mercury doses by age and vaccine under two hepatitis B schemes, along with tetanus toxoid doses for women of childbearing age. The note adds that maternal doses do not reach levels of concern, though the effect on the fetal brain is uncertain, and lists knowledge gaps, such as the comparative toxicity of ethylmercury and methylmercury, that make the exact risk hard to identify.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-231031/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "rently exclude the possibility of subtle neurodevelopmental\nabnormalities from a cumulative exposure of infants to\nthiomersal in vaccines.\n\nDespite a lack of direct evidence of harmful effects of the\npreservative in vaccines, change seems inevitable.\nHowever, the goal of reducing mercury exposure from\nthiomersal in vaccines creates several problems for\nnational immunization programmes. If the condemnation\nof thiomersal were to be too strong, many vital vaccines\nmight be withdrawn from production. If the issue were to\nbe ignored, increasing amounts of thiomersal would be\ninjected into children",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues, in parallel English and French, a Weekly Epidemiological Record article on thiomersal in vaccines, noting there is no direct evidence of harm but that cutting mercury exposure poses dilemmas for national immunization programmes. Its bilingual summary judges the theoretical low neurodevelopmental risk to be far outweighed by the dangers of vaccine-preventable disease and contaminated multidose vials, and describes short- and long-term plans by WHO and other agencies to reduce and possibly eliminate the preservative. The page also explains that removing thiomersal would raise contamination risks, strain manufacturers, local producers and the cold chain, while monodose vials are too costly for developing countries and any substitute preservative would take time to license.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-231031/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "relicensing, and even with a “fast track” procedure, could\ntake over a year to process.\n\nCombination vaccines have been proposed as a means of\nreducing cold-chain requirements and improving coverage\nby delivering multiple antigens in fewer injections. Also,\nthe amount of preservative needed per vial is the same\nwhether it contains one or many antigens. Thus as more\nantigens are included in a combination vaccine, there will\nbe the need for proportionately less preservative per dose\nof antigen.\n\nNew preservative-free vaccine delivery systems are under\nconstruction. Systems such as powdered jet i",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Concludes the bilingual thiomersal article, noting that relicensing a vaccine with a new preservative could take over a year, that combination vaccines need less preservative per antigen dose, and that preservative-free delivery systems such as powdered jet injection are in development. The page then carries the record's standard notes on geographical designations and on the duty under Article 3 of the International Health Regulations to notify WHO within 24 hours of a first case. It ends with a partly garbled table of cholera and yellow fever notifications received from 7 to 13 January 2000, covering countries in Africa, Asia and the Americas.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
